Who Owns Savient Pharmaceuticals, Inc. Remnant Assets?
Oak Point Partners, Inc. acquired the remnant assets of the Savient Pharmaceuticals, Inc. Bankruptcy Estate in May 2014.
On October 14, 2013, Savient Pharmaceuticals, Inc. filed a chapter 11 petition in the United States Bankruptcy Court for the District of Delaware, assigned Case No. 13-12680. Thereafter, a trustee was charged with winding down the estate for the benefit of creditors. Oak Point Partners, Inc. acquired the remnant assets of the Savient Pharmaceuticals, Inc. Bankruptcy Estate in May 2014.
Related Entities: Androtab, Androtest-SL, Bio-Hep-B, Biolon, Bio-Technology General Corp., Bio-Tropin, Delatestryl, Deplic, Euflexxa, Exercase, Factorex, Fibrimage, Gynex Pharmaceuticals, Inc., Gynex, Inc., Hepandrin, Imagex, Lipidex, Myelos Corporation, Neuro Hi-Tech, Nuflexxa, Oxandrin, OxSODrol, Prosaptide, Puricase, Savient Pharma Holdings, Inc., Silkis, Tophix, Tophuric, URIXIV
Contact Information Regarding Payments to Savient Pharmaceuticals, Inc.
Inquiries regarding where to send: Overpayments, Undeliverable Funds, Insurance Refunds, Refunds, Warrants, Unclaimed Funds, Rebates, Uncashed Checks, Restitution, Credit Balance, Escheat, Judgment Balance, Abandoned Property, Settlement Proceeds, or any other funds belonging to Savient Pharmaceuticals, Inc..
Requests for reasonable referral or finder fees will be considered.
Contact Info: Savient Pharmaceuticals, Inc.
About Savient Pharmaceuticals, Inc.
Incorporated in 1980, Savient Pharmaceuticals was a specialty biopharmaceutical company that was a developer of a treatment for gout. Savient Pharmaceuticals also sold generic and branded drugs used to promote weight gain following involuntary weight loss. The company employed 82 people.
Savient Pharmaceuticals also operated as Bio-Technology General Corp and Gynex.
The former headquarters of Savient Pharmaceuticals was in Bridgewater, New Jersey.